Event JSON
{
"id": "64ba797af48edaa31098b9bb8883fb285e598bee374e0cd9fe6b82ab3fc27273",
"pubkey": "523e7d5b69a98a9c3374105934ca42aa132465e5f899713127ffbc843532945c",
"created_at": 1736187081,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/video/why-2025-inflection-novo-nordisk-180000345.html"
],
[
"subject",
"Why 2025 will be an inflection for Novo Nordisk, Eli Lilly's GLP-1s"
],
[
"published_at",
"1736186400"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/iJ6s2L2SKsc8kUjU4G2Q3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/2ef84540-cc4f-11ef-b7d3-e4f72e0784fb"
],
[
"p",
"523e7d5b69a98a9c3374105934ca42aa132465e5f899713127ffbc843532945c",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/iJ6s2L2SKsc8kUjU4G2Q3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/2ef84540-cc4f-11ef-b7d3-e4f72e0784fb"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"Emily Field, head of European pharmaceuticals research at Barclays, joins Morning Brief to discuss her outlook for the GLP-1 market in 2025. She notes that both Novo Nordisk and Eli Lilly have clinical catalysts scheduled throughout the year, but expects the prescription data to drive revenue upside and impact the sector. Field also mentions that both companies have invested billions in capacity expansion, which will likely start to show benefits in 2025."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq2gl86kmf4x9fcvm5zpvnfjjz4gfjge09lzvhzvf8l77ggdfjj3wq39gnh6\nhttps://s.yimg.com/ny/api/res/1.2/iJ6s2L2SKsc8kUjU4G2Q3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/2ef84540-cc4f-11ef-b7d3-e4f72e0784fb\n\nhttps://finance.yahoo.com/video/why-2025-inflection-novo-nordisk-180000345.html",
"sig": "291656e1e310b13b15536e418a5fab2cd7a8049091882a73c8f2a660ac98d907e76f4c167930c6283164d8964438321510d08a56cb2bd3898c2b1550459bcbfa"
}